Molbio Diagnostics Sets IPO Price Band At ₹768-807; Issue Opens On August 10
· Free Press Journal
New Delhi, August 5, 2026: Point-of-care diagnostics company Molbio Diagnostics Ltd, backed by Temasek and Motilal Oswal Private Equity, on Wednesday fixed a price band of Rs 768-807 per share for its Initial Public Offering (IPO), which will open for subscription on August 10.
Visit michezonews.co.za for more information.
IPO Details
The initial share sale, estimated at Rs 904 crore to Rs 940 crore at the lower and upper ends of the price band, respectively, will conclude on August 12.
The bidding for anchor investors will open on August 7, according to the company's public announcement.
The Goa-based company's IPO comprises a fresh issue of shares worth up to Rs 200 crore and an Offer for Sale (OFS) of up to 91.66 lakh equity shares by existing shareholders.
Under the OFS, Exxora Trading LLP, Dr Chandrasekhar Bhaskaran Nair, India Business Excellence Fund III, Gopalkrishna Mangalore Kini, J. Guru Dutt, Gopalakrishna Sampathgiri, Sangeetha M. Kini, M.A. Usha Rani, M.A. Rohit, Shruthi G. Kini and several other shareholders will divest their stakes.
Utilisation Of Proceeds
The company proposes to utilise Rs 106 crore from the fresh issue proceeds towards capital expenditure for setting up infrastructure for an R&D facility, Centre of Excellence and connected office space.
Another Rs 72 crore will be deployed towards the purchase of plant, machinery and other equipment for its Goa Unit I, Goa Unit II and Visakhapatnam unit, while the remaining funds will be used for general corporate purposes.
At the upper end of the price band, Molbio Diagnostics is expected to command a post-issue market valuation of around Rs 9,300 crore.
Half of the issue has been reserved for qualified institutional buyers, 15 per cent for non-institutional investors and 35 per cent for retail investors.
Company Profile
Incorporated in 2000, Molbio Diagnostics is a point-of-care diagnostics company offering molecular testing for 30 diseases, including tuberculosis, COVID-19, HIV, HPV, and Hepatitis B and C.
Its 'Truenat' platform, patented in more than 100 countries for the diagnosis of multiple infectious and non-communicable diseases, is a point-of-care polymerase chain reaction (PCR) platform. The battery-operated platform can be deployed in resource-limited settings and facilitates decentralised diagnosis within an hour.
The company has six manufacturing facilities in India—two in Goa, two in Bengaluru, and one each in Visakhapatnam and Pune.
As of March 31, 2026, Molbio's installed capacity stood at 5,400 devices per annum and 3.9 crore Truenat test kits annually.
Also Watch:
Dhoot Transmission Unveils ₹3,067-Crore IPO, Fixes Price Band At ₹829-871 Ahead Of August 10 LaunchFinancial Performance
On the financial front, the company's revenue from operations stood at Rs 1,445 crore in fiscal 2026, while profit stood at Rs 164 crore during the period.
The company's shares are proposed to be listed on the BSE and NSE on August 17.
Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors are the book-running lead managers to the issue.
(Disclaimer: Except for the headline, this article has not been edited by FPJ's editorial team and is auto-generated from an agency feed.)